MRPL11 (mitochondrial ribosomal protein L11) is a structural component of the mitochondrial large ribosomal subunit that plays a critical role in mitochondrial translation. It functions as part of the L7/L12 stalk complex alongside MRPL10 and MRPL12, which is essential for recruiting initiation and elongation factors during protein synthesis 1. MRPL11 binds to mitochondrial large ribosomal subunit rRNA and participates in the translation of mitochondrial-encoded proteins required for oxidative phosphorylation. Dysregulation of MRPL11 expression associates with multiple disease states. In head and neck squamous cell carcinoma, decreased MRPL11 expression correlates with impaired mitochondrial translation and reduced OXPHOS complex subunit expression in metastatic tumors 2. MRPL11 was identified as one of four stemness-associated genes significantly upregulated in intrahepatic cholangiocarcinoma, where it promotes cancer stem cell self-renewal and chemoresistance through activation of the methionine cycle 3. Conversely, MRPL11 is downregulated in venous thromboembolism, clustering with other mitochondrial ribosomal proteins in a pathway associated with reduced mitochondrial translation 4. In cervical cancer, MRPL11 expression correlates with metastatic phenotypes characterized by rapid proliferation and oxidative phosphorylation 5. Additionally, MRPL11 appears dysregulated in diabetic kidney disease and serves as a hub gene in COVID-19 and preeclampsia, suggesting broad involvement in mitochondrial dysfunction-related pathologies 6, 7.